| Identification | Back Directory | [Name]
Tecadenoson | [CAS]
204512-90-3 | [Synonyms]
CVT-510
N6-[3(R)-Tetrahydrofuranyl]adenosine
Adenosine, N-[(3R)-tetrahydro-3-furanyl]-
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-(((R)-tetrahydrofuran-3-yl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | [Molecular Formula]
C14H19N5O5 | [MOL File]
204512-90-3.mol | [Molecular Weight]
337.33 |
| Chemical Properties | Back Directory | [Boiling point ]
704.9±70.0 °C(Predicted) | [density ]
1.89±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C(protect from light) | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: Partially soluble; PBS (pH 7.2): 3 mg/ml | [form ]
A crystalline solid | [pka]
13.11±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Tecadenoson is an analog of adenosine. Tecadenoson works by activating two types of receptors: A1 and A2A. Activation of these receptors leads to increased blood supply, which improves symptoms in patients with chronic obstructive pulmonary disease. Tecadenoson has also been shown to reduce inflammation and improve lung function in animal models of asthma. Tecadenoson is not active against bacterial infections or viral infections, but is effective against autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, and vasculitis. | [Uses]
Tecadenoson, is a selective A1 adenosine receptor agonist. | [Uses]
Treatment of paroxysmal supraventricular
tachycardia and rate control in atrial fibrillation
and atrial flutter. | [in vivo]
In atrial-paced anaesthetized guinea-pigs, intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval[1]. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson given at 50 μg/kg causes a significant bradycardia (50% decrease in heart rate at 25 min[2]. | [storage]
Store at -20°C |
|
|